target,target_id,target_uniprot,target_species,ligand,ligand_id,ligand_species,ligand_pubchem_cid,smiles,inchi,inchikey,type,action,action_comment,endogenous,primary_target,concentration_range,affinity_parameter,affinity_high,affinity_median,affinity_low,original_affinity_units,original_affinity_low_nm,original_affinity_median_nm,original_affinity_high_nm,original_affinity_relation,assay_description,receptor_site,ligand_context,pubmed_id dihydrofolate reductase,2603,P00374,Human,methotrexate,4815,,126941,OC(=O)CC[C@@H](C(=O)O)NC(=O)c1ccc(cc1)N(Cc1cnc2c(n1)c(N)nc(n2)N)C,"InChI=1S/C20H22N8O5/c1-28(9-11-8-23-17-15(24-11)16(21)26-20(22)27-17)12-4-2-10(3-5-12)18(31)25-13(19(32)33)6-7-14(29)30/h2-5,8,13H,6-7,9H2,1H3,(H,25,31)(H,29,30)(H,32,33)(H4,21,22,23,26,27)/t13-/m0/s1",FBOZXECLQNJBKD-ZDUSSCGKSA-N,Inhibitor,Inhibition,,,yes,,pKi,,8.92,,Ki,,1.2,,=,,,,7877140, dihydrofolate reductase,2603,P00374,Human,pemetrexed,6837,,135565230,OC(=O)CC[C@H](C(=O)O)NC(=O)c1ccc(cc1)CCc1c[nH]c2c1c(=O)nc([nH]2)N,"InChI=1S/C20H21N5O6/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29)/t13-/m1/s1",WBXPDJSOTKVWSJ-CYBMUJFWSA-N,Inhibitor,Inhibition,,,yes,,pKi,,8.15,,Ki,,7.0,,=,,,,16078850|9762351, dihydrofolate reductase,2603,P00374,Human,pralatrexate,6840,,148121,C#CCC(c1ccc(cc1)C(=O)N[C@H](C(=O)O)CCC(=O)O)Cc1cnc2c(n1)c(N)nc(n2)N,"InChI=1S/C23H23N7O5/c1-2-3-14(10-15-11-26-20-18(27-15)19(24)29-23(25)30-20)12-4-6-13(7-5-12)21(33)28-16(22(34)35)8-9-17(31)32/h1,4-7,11,14,16H,3,8-10H2,(H,28,33)(H,31,32)(H,34,35)(H4,24,25,26,29,30)/t14?,16-/m0/s1",OGSBUKJUDHAQEA-WMCAAGNKSA-N,Inhibitor,Inhibition,,,yes,,pKi,,7.35,,Ki,,45.0,,=,,,,19221750, dihydrofolate reductase,2603,P00374,Human,diflunisal,7162,,3059,Fc1ccc(c(c1)F)c1ccc(c(c1)C(=O)O)O,"InChI=1S/C13H8F2O3/c14-8-2-3-9(11(15)6-8)7-1-4-12(16)10(5-7)13(17)18/h1-6,16H,(H,17,18)",HUPFGZXOMWLGNK-UHFFFAOYSA-N,Inhibitor,Inhibition,This is well below the peak plasma diflunisal levels reached at typical clinically administered doses.,,,,pKi,,4.47,,Ki,,34000.0,,=,,,,, dihydrofolate reductase,2603,P00374,Human,trimetrexate,7613,,5583,COc1cc(NCc2ccc3c(c2C)c(N)nc(n3)N)cc(c1OC)OC,"InChI=1S/C19H23N5O3/c1-10-11(5-6-13-16(10)18(20)24-19(21)23-13)9-22-12-7-14(25-2)17(27-4)15(8-12)26-3/h5-8,22H,9H2,1-4H3,(H4,20,21,23,24)",NOYPYLRCIDNJJB-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pKi,,7.89,,Ki,,13.0,,=,In vitro inhibition of wild-type human DHFR,,,7877140, dihydrofolate reductase,2603,P00374,Human,compound 9 [PMID: 15615544],8890,,11247965,OC(=O)CC[C@H](N1Cc2c(C1=O)ccc(c2)NCc1cnc2c(n1)c(N)nc(n2)N)C(=O)O,"InChI=1S/C20H20N8O5/c21-16-15-17(27-20(22)26-16)24-7-11(25-15)6-23-10-1-2-12-9(5-10)8-28(18(12)31)13(19(32)33)3-4-14(29)30/h1-2,5,7,13,23H,3-4,6,8H2,(H,29,30)(H,32,33)(H4,21,22,24,26,27)/t13-/m0/s1",NYPQVENKFXVRKJ-ZDUSSCGKSA-N,Inhibitor,Inhibition,,,,,pKi,,10.47,,Ki,,0.034,,=,,,,15615544, dihydrofolate reductase,2603,P00374,Human,iclaprim,10820,,213043,COc1cc(Cc2cnc(nc2N)N)c2c(c1OC)OC(C=C2)C1CC1,"InChI=1S/C19H22N4O3/c1-24-15-8-11(7-12-9-22-19(21)23-18(12)20)13-5-6-14(10-3-4-10)26-16(13)17(15)25-2/h5-6,8-10,14H,3-4,7H2,1-2H3,(H4,20,21,22,23)",HWJPWWYTGBZDEG-UHFFFAOYSA-N,Inhibitor,Inhibition,,,,,pKi,,6.11,,Ki,,775.0,,=,,,,,